237 related articles for article (PubMed ID: 29219615)
21. Multiple Myeloma Gets Three New Drugs.
Poh A
Cancer Discov; 2016 Jan; 6(1):4. PubMed ID: 26658418
[TBL] [Abstract][Full Text] [Related]
22. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Salvini M; Bonello F; Boccadoro M; Larocca A
Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
[TBL] [Abstract][Full Text] [Related]
23. Ixazomib for multiple myeloma.
Burki TK
Lancet Oncol; 2016 Jun; 17(6):e228. PubMed ID: 27160477
[No Abstract] [Full Text] [Related]
24. [New drugs in the treatment of multiple myeloma].
Oriol A; Motlló C
Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
[TBL] [Abstract][Full Text] [Related]
25. Novel Approaches for the Management of AL Amyloidosis.
Joseph NS; Kaufman JL
Curr Hematol Malig Rep; 2018 Jun; 13(3):212-219. PubMed ID: 29951831
[TBL] [Abstract][Full Text] [Related]
26. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
27. Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Mina R; Falcone AP; Bringhen S; Liberati AM; Pescosta N; Petrucci MT; Ciccone G; Capra A; Patriarca F; Rota-Scalabrini D; Bonello F; Musolino C; Cea M; Zambello R; Tacchetti P; Belotti A; Cellini C; Paris L; Grasso M; Aquino S; De Paoli L; De Sabbata G; Ballanti S; Offidani M; Boccadoro M; Monaco F; Corradini P; Larocca A
Blood Cancer J; 2021 Dec; 11(12):197. PubMed ID: 34876566
[No Abstract] [Full Text] [Related]
28. Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Salcedo M; Lendvai N; Mastey D; Schlossman J; Hultcrantz M; Korde N; Mailankody S; Lesokhin A; Hassoun H; Smith E; Shah U; Diab V; Werner K; Landau H; Lahoud O; Drullinsky P; Shah G; Chung D; Scordo M; Giralt S; Landgren O
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):198-200. PubMed ID: 32001193
[No Abstract] [Full Text] [Related]
29. Frontline regimens for multiple myeloma patients.
Lonial S
Clin Adv Hematol Oncol; 2010 May; 8(5):331-2. PubMed ID: 20551891
[No Abstract] [Full Text] [Related]
30. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Laubach JP; Paba Prada CE; Richardson PG; Longo DL
Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
[TBL] [Abstract][Full Text] [Related]
31. [Current development of new drugs in malignant lymphoma].
Ogura M
Nihon Rinsho; 2012 Apr; 70 Suppl 2():715-30. PubMed ID: 23134034
[No Abstract] [Full Text] [Related]
32. Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Tian C; Yang H; Zhu L; Zhang Q; Cao Z; Zhang Y
Ann Hematol; 2017 Aug; 96(8):1407-1410. PubMed ID: 28577043
[No Abstract] [Full Text] [Related]
33. Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations.
Rajan AM; Buadi FK; Rajkumar V
Am J Hematol; 2016 Feb; 91(2):E5-6. PubMed ID: 26572926
[No Abstract] [Full Text] [Related]
34. Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
Zhang K; Desai A; Zeng D; Gong T; Lu P; Wang M
Oncotarget; 2017 Feb; 8(6):10748-10759. PubMed ID: 27863374
[TBL] [Abstract][Full Text] [Related]
35. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
36. [Carfilzomib in multiple myeloma relapses].
Bay JO
Bull Cancer; 2015 Feb; 102(2):116. PubMed ID: 25874287
[No Abstract] [Full Text] [Related]
37. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
[TBL] [Abstract][Full Text] [Related]
38. FDA approves three different multiple myeloma drugs in one month.
Ratner M
Nat Biotechnol; 2016 Feb; 34(2):126. PubMed ID: 26849508
[No Abstract] [Full Text] [Related]
39. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.
Schönfeld K; Zuber C; Pinkas J; Häder T; Bernöster K; Uherek C
J Hematol Oncol; 2017 Jan; 10(1):13. PubMed ID: 28077160
[TBL] [Abstract][Full Text] [Related]
40. Pomalidomide: when expectations are understated.
Di Raimondo F; Conticello C
Future Oncol; 2017 Feb; 13(5s):1-2. PubMed ID: 28116940
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
